GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regulus Therapeutics Inc (NAS:RGLS) » Definitions » 3-Year Dividend Growth Rate

RGLS (Regulus Therapeutics) 3-Year Dividend Growth Rate : 0.00% (As of Dec. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Regulus Therapeutics 3-Year Dividend Growth Rate?

Regulus Therapeutics's Dividends per Share for the three months ended in Dec. 2024 was $0.00.

The historical rank and industry rank for Regulus Therapeutics's 3-Year Dividend Growth Rate or its related term are showing as below:

RGLS's 3-Year Dividend Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 10.2
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Regulus Therapeutics's Dividend Payout Ratio for the three months ended in Dec. 2024 was 0.00. As of today, Regulus Therapeutics's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Regulus Therapeutics's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Regulus Therapeutics's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regulus Therapeutics's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regulus Therapeutics's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Regulus Therapeutics's 3-Year Dividend Growth Rate falls into.


;
;

Regulus Therapeutics 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Regulus Therapeutics  (NAS:RGLS) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Regulus Therapeutics's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2024 )/ EPS without NRI (Q: Dec. 2024 )
=0/ -0.2
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regulus Therapeutics 3-Year Dividend Growth Rate Related Terms>

Regulus Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regulus Therapeutics Inc (NAS:RGLS) » Definitions » 3-Year Dividend Growth Rate
Comparable Companies
TVGN YMAB DRTS INMB HURA CDXS INBX SGMO TVRD FULC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
7RG0:Germany 7RG0:Germany
Address
4224 Campus Point Court, Suite 210, San Diego, CA, USA, 92121
Website
https://www.regulusrx.com
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
Executives
David Baltimore director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Joseph P Hagan officer: Chief Operating Officer 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Christopher Ray Aker officer: Sr. VP & General Counsel C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Crispina Calsada officer: Chief Financial Officer C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Preston Klassen officer: President & Head of R & D 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Kathryn J Collier director C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Denis Drygin officer: Chief Scientific Officer 10628 SCIENCE CENTER DRIVE, SUITE 225, SAN DIEGO CA 92121
Alice Shih-hou Huang director 10628 SCIENCE CENTER DRIVE, SUITE 225, SAN DIEGO CA 92121
Growth Equity Opportunities V, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ali Behbahani 10 percent owner 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Paul Edward Walker director 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Scott D Sandell 10 percent owner
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025